Literature DB >> 23645684

The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.

Tracey M Doyle1, Bozena Jaentschke, Gary Van Domselaar, Anwar M Hashem, Aaron Farnsworth, Nicole E Forbes, Changgui Li, Junzhi Wang, Runtao He, Earl G Brown, Xuguang Li.   

Abstract

The only universally conserved sequence among all influenza A viral neuraminidases is located between amino acids 222 and 230. However, the potential roles of these amino acids remain largely unknown. Through an array of experimental approaches including mutagenesis, reverse genetics, and growth kinetics, we found that this sequence could markedly affect viral replication. Additional experiments revealed that enzymes with mutations in this region demonstrated substantially decreased catalytic activity, substrate binding, and thermostability. Consistent with viral replication analyses and enzymatic studies, protein modeling suggests that these amino acids could either directly bind to the substrate or contribute to the formation of the active site in the enzyme. Collectively, these findings reveal the essential role of this unique region in enzyme function and viral growth, which provides the basis for evaluating the validity of this sequence as a potential target for antiviral intervention and vaccine development.

Entities:  

Keywords:  Enzyme Mutation; Epitope Mapping; Influenza Virus; Influenza Virus Replication; Neuraminidase; Structural Stability; Substrate Binding; Thermodynamics; Universal Epitope; Viral Replication

Mesh:

Substances:

Year:  2013        PMID: 23645684      PMCID: PMC3689970          DOI: 10.1074/jbc.M113.468884

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Combinatorial alanine-scanning.

Authors:  K L Morrison; G A Weiss
Journal:  Curr Opin Chem Biol       Date:  2001-06       Impact factor: 8.822

2.  Structural and energetic consequences of disruptive mutations in a protein core.

Authors:  W A Lim; D C Farruggio; R T Sauer
Journal:  Biochemistry       Date:  1992-05-05       Impact factor: 3.162

3.  Roles of neuraminidase in the initial stage of influenza virus infection.

Authors:  Masanobu Ohuchi; Naoko Asaoka; Tatsuya Sakai; Reiko Ohuchi
Journal:  Microbes Infect       Date:  2006-02-08       Impact factor: 2.700

4.  Three-dimensional structure of a complex of antibody with influenza virus neuraminidase.

Authors:  P M Colman; W G Laver; J N Varghese; A T Baker; P A Tulloch; G M Air; R G Webster
Journal:  Nature       Date:  1987 Mar 26-Apr 1       Impact factor: 49.962

Review 5.  The neuraminidase of influenza virus.

Authors:  G M Air; W G Laver
Journal:  Proteins       Date:  1989

6.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.

Authors:  M Potier; L Mameli; M Bélisle; L Dallaire; S B Melançon
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

7.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

8.  Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases.

Authors:  Anwar M Hashem; Anathea S Flaman; Aaron Farnsworth; Earl G Brown; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

Review 9.  Antigenic variation and the structure of influenza virus glycoproteins.

Authors:  W G Laver
Journal:  Microbiol Sci       Date:  1984-05

Review 10.  The molecular biology of influenza virus pathogenicity.

Authors:  H D Klenk; R Rott
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

View more
  14 in total

1.  Dynamic Perspectives on the Search for a Universal Influenza Vaccine.

Authors:  Chadi M Saad-Roy; Adrian B McDermott; Bryan T Grenfell
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

2.  Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.

Authors:  Ye Wang; Lei Deng; Gilbert X Gonzalez; Latika Luthra; Chunhong Dong; Yao Ma; Jun Zou; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Adv Healthc Mater       Date:  2019-12-15       Impact factor: 9.933

3.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

4.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.

Authors:  Lianlian Jiang; Giovanna Fantoni; Laura Couzens; Jin Gao; Ewan Plant; Zhiping Ye; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

5.  Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Authors:  Wen-Chun Liu; Chia-Ying Lin; Yung-Ta Tsou; Jia-Tsrong Jan; Suh-Chin Wu
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

6.  Influenza A surface glycosylation and vaccine design.

Authors:  Chung-Yi Wu; Chih-Wei Lin; Tsung-I Tsai; Chang-Chun David Lee; Hong-Yang Chuang; Jhih-Bin Chen; Ming-Hung Tsai; Bo-Rui Chen; Pei-Wen Lo; Chiu-Ping Liu; Vidya S Shivatare; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-27       Impact factor: 11.205

7.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Authors:  E R Job; M Schotsaert; L I Ibañez; A Smet; T Ysenbaert; K Roose; M Dai; C A M de Haan; H Kleanthous; T U Vogel; X Saelens
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

9.  Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.

Authors:  Francisco Miguel Cardoso; Lorena Itatí Ibañez; Silvie Van den Hoecke; Sarah De Baets; Anouk Smet; Kenny Roose; Bert Schepens; Francis J Descamps; Walter Fiers; Serge Muyldermans; Ann Depicker; Xavier Saelens
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

10.  Ethical alternatives to experiments with novel potential pandemic pathogens.

Authors:  Marc Lipsitch; Alison P Galvani
Journal:  PLoS Med       Date:  2014-05-20       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.